Skip to main content

Advertisement

Figure 2 | BMC Infectious Diseases

Figure 2

From: Cost-effectiveness of posaconazole versusfluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain

Figure 2

Probabilistic sensitivity analysis (PSA); incremental cost-effectiveness ratio (ICER) of posaconazole versus SAT (standard azole treatment; fluconazole or itraconazole) in the prevention of invasive fungal infection (IFI) among high-risk neutropenic patients (ICER threshold considered is €30,000 per life-year saved).

Back to article page